Veröffentlichungen von Mitgliedern
M. Hoffmann, N. Gaisa, R. Nawroth und T. Ecke haben als Editoren gemeinsam mit nationalen und internationalen Kolleg*innen gestaltet, erschienen beim Springer Verlag.
Methoden Buch zum Urothelkarzinom 2. Ausgabe
BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, and CancerCheck® UBC® rapid VISUAL as urinary marker for bladder cancer: Final results of a German multicenter study. Ecke TH, Meisl CJ, Schlomm T, Rabien A, Labonté F, Rong D, Hofbauer S, Friedersdorff F, Sommerfeldt L, Gagel N, Gössl A, Barski D, Otto T, Grunewald CM, Niegisch G, Hennig MJP, Kramer MW, Koch S, Roggisch J, Hallmann S, Weiß S, Waldner M, Graff J, Veltrup E, Linden F, Hake R, Eidt S, Wirtz RM. Urol Oncol 2023
Nomograms including the UBC® Rapid test to detect primary bladder cancer based on a multicentre dataset. Meisl C, Karakiewicz P, Einarsson R, Koch S, Hallmann S, Weiß S, Hemdan T, Malmström PU, Styrke J, Sherif A, Hasan M, Pichler R, Tulchiner G, Palou J, Rodriguez Faba O, Hennenlotter J, Stenzl A, Ritter R, Niegisch G, Grunewald C, Schlomm T, Friedersdorff F, Barski D, Otto T, Gössl A, Arndt C, Esuvaranathan K, Kesavan N, Zhijiang Z, Kramer M, Henning M, Ecke T. BJU Int 2022 Dec;130(6):754-763. doi: 10.1111/bju.15677. Epub 2022 Jan 11
Prediction of Response to Cisplatin-Based Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer Patients by Molecular Subtyping including KRT and FGFR Target Gene Assessment. Ecke TH, Voß PC, Schlomm T, Rabien A, Friedersdorff F, Barski D, Otto T, Waldner M, Veltrup E, Linden F, Hake R, Eidt S, Roggisch J, Heidenreich A, Rieger K, Kastner L, Hallmann S, Koch S, Wirtz RM. Int. J. Mol. Sci. 2022 Jul 18;23(14):7898. doi: 10.3390/ijms23147898.
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation. Morsch R, Rose M, Maurer A, Cassataro MA, Braunschweig T, Knüchel R, Vögeli TA, Ecke T, Eckstein M, Weyerer V, Esposito I, Ackermann M, Niegisch G, Gaisa NT; German Study Group of Bladder Cancer (DFBK e.V.). BMC Cancer. 2020 Mar 18;20(1):230. doi: 10.1186/s12885-020-06727-2. PMID: 32188412
MMP-7 Serum and Tissue Levels Are Associated with Poor Survival in Platinum-Treated Bladder Cancer Patients. Szarvas T, Hoffmann MJ, Olah C, Szekely E, Kiss A, Hess J, Tschirdewahn S, Hadaschik B, Grotheer V, Nyirady P, Csizmarik A, Varadi M, Reis H. Diagnostics (Basel). 2020 Dec 31;11(1):48. doi: 10.3390/diagnostics11010048. PMID: 33396213
Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients. Olah C, Tschirdewahn S, Hoffmann MJ, Krafft U, Hadaschik B, Nyirady P, Szendröi A, Módos O, Csizmarik A, Kovalszky I, Reis H, Szarvas T. Diagnostics (Basel). 2020 Oct 23;10(11):864. doi: 10.3390/diagnostics10110864. PMID: 33114033
ITIH5 and ECRG4 DNA Methylation Biomarker Test (EI-BLA) for Urine-Based Non-Invasive Detection of Bladder Cancer . Rose M, Bringezu S, Godfrey L, Fiedler D, Gaisa NT, Koch M, Bach C, Füssel S, Herr A, Hübner D, Ellinger J, Pfister D, Knüchel R, Wirth MP, Böhme M, Dahl E. Int J Mol Sci. 2020 Feb 7;21(3):1117. doi: 10.3390/ijms21031117. PMID: 32046186 Free PMC article
High-soluble CGA levels are associated with poor survival in bladder cancer. Szarvas T, Jardin-Watelet B, Bourgoin N, Hoffmann MJ, Nyirády P, Oláh C, Széll T, Csizmarik A, Hadaschik B, Reis H. Endocr Connect. 2019 May 1;8(5):625-633. doi: 10.1530/EC-19-0068. PMID: 30999279
SWI/SNF Alterations in Squamous Bladder Cancers. Achenbach F, Rose M, Ortiz-Brüchle N, Seillier L, Knüchel R, Weyerer V, Hartmann A, Morsch R, Maurer A, Ecke TH, Garczyk S, Gaisa NT. Genes (Basel). 2020 Nov 19;11(11):1368. doi: 10.3390/genes11111368. PMID: 33227989
Comparative genomic profiling of glandular bladder tumours. Maurer A, Ortiz-Bruechle N, Guricova K, Rose M, Morsch R, Garczyk S, Stöhr R, Bertz S, Golz R, Reis H, Bremmer F, Zimpfer A, Siegert S, Kristiansen G, Schwamborn K, Gassler N, Knuechel R, Gaisa NT; German study group of bladder cancer. Virchows Arch. 2020 Sep;477(3):445-454. doi: 10.1007/s00428-020-02787-8. Epub 2020 Mar 20. PMID: 32198650
Prevalence of APC and PTEN Alterations in Urachal Cancer. Nagy N, Reis H, Hadaschik B, Niedworok C, Módos O, Szendrői A, Bíró K, Hager T, Herold T, Ablat J, Black PC, Okon K, Tolkach Y, Csizmarik A, Oláh C, Keresztes D, Bremmer F, Gaisa NT, Kriegsmann J, Kovalszky I, Kiss A, Tímár J, Szász MA, Rink M, Fisch M, Nyirády P, Szarvas T. Pathol Oncol Res. 2020 Oct;26(4):2773-2781. doi: 10.1007/s12253-020-00872-6. Epub 2020 Aug 4. PMID: 32754865
Applying the chicken embryo chorioallantoic membrane assay to study treatment approaches in urothelial carcinoma. Skowron MA , Sathe A, Romano A, Hoffmann MJ , Schulz WA, van Koeveringe GA , Albers P, Nawroth R, Niegisch G. Urol Oncol, 2017 Sep;35(9):544.e11-544.e23. doi: 10.1016/j.urolonc.2017.05.003. Epub 2017 May 25. PMID: 28551413
Multiregion human bladder cancer sequencing reveals tumour evolution, bladder cancer phenotypes and implications for targeted therapy. Heide T, Maurer A, Eipel M, Knoll K, Geelvink M, Veeck J, Knuechel R, van Essen J, Stoehr R, Hartmann A, Altmueller J, Graham TA, Gaisa NT. J Pathol. 2019 Jun;248(2):230-242. doi: 10.1002/path.5250. Epub 2019 Mar 18. PMID: 30719704
A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancer. Stubendorff B, Wilhelm K, Posselt K, Catto J, Hartmann A, Bertz S, Füssel S, Novotny V, Toma M, Gajda M, Lehmann J, Wunderlich H, Grimm MO, Stöckle M, Junker K. J Cancer Res Clin Oncol. 2019 Apr;145(4):811-820. doi: 10.1007/s00432-018-02829-4. Epub 2019 Jan 2. PMID: 30603903
Book: Urothelial Carcinoma: Methods and Protocols
Editors: Wolfgang A Schulz, Michèle J. Hoffmann, Günter Niegisch
Springer Protocols, 2018
https://www.springer.com/de/book/9781493972333
A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. Eckstein M, Wirtz RM, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, Günes C, Nitschke K, Weichert W, Otto W, Keck B, Eidt S, Burger M, Taubert H, Wullich B, Bolenz C, Hartmann A, Erben P. Oncotarget. 2018 Feb 19;9(19):15001-15014. doi: 10.18632/oncotarget.24531. eCollection 2018 Mar 13. PMID: 29599921
Knockdown of UTX/KDM6A Enriches Precursor Cell Populations in Urothelial Cell Cultures and Cell Lines. Lang A, Whongsiri P, Yilmaz M, Lautwein T, Petzsch P, Greife A, Günes C, Köhrer K, Niegisch G, Hoffmann M, Schulz WA. Cancers (Basel). 2020 Apr 21;12(4):1023. doi: 10.3390/cancers12041023. PMID: 32326336
EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer. Rose M, Maurer A, Wirtz J, Bleilevens A, Waldmann T, Wenz M, Eyll M, Geelvink M, Gereitzig M, Rüchel N, Denecke B, Eltze E, Herrmann E, Toma M, Horst D, Grimm T, Denzinger S, Ecke T, Vögeli TA, Knuechel R, Maurer J, Gaisa NT. Oncogene. 2020 Oct;39(44):6856-6870. doi: 10.1038/s41388-020-01465-y. Epub 2020 Sep 25. PMID: 32978523
Bladder cancer documentation of causes: multilingual questionnaire, ‚bladder cancer doc‘. Golka K, Abreu-Villaca Y, Anbari Attar R, Angeli-Greaves M, Aslam M, Basaran N, Belik R, Butryee C, Dalpiaz O, Dzhusupov K, Ecke TH, Galambos H, Galambos H, Gerilovica H, Gerullis H, Gonzalez PC, Goossens ME, Gorgishvili-Hermes L, Heyns CF, Hodzic J, Ikoma F, Jichlinski P, Kang BH, Kiesswetter E, Krishnamurthi K, Lehmann ML, Martinova I, Mittal RD, Ravichandran B, Romics I, Roy B, Rungkat-Zakaria F, Rydzynski K, Scutaru C, Shen J, Soufi M, Toguzbaeva K, Vu Duc T, Widera A, Wishahi M, Hengstler JG. Front Biosci (Elite Ed). 2012 Jun 1;4:2709-22. doi: 10.2741/e585. PMID: 22652680
Bladder cancer in focus: Update 2012 of the German Bladder Cancer Association
Keck B, Merseburger AS, Stöhr R, Füssel S, Hoffmann MJ, Schmid S, Olbert P, Hartmann A, Nawroth R
Urologe A. 2013 Jan 30.
Bladder cancer at an early age in father and son
Ovsiannikov D, Stöhr R, Hartmann A, Böttrich R, Hengstler JG, Golka K
Urologe A. 2011 Dec;50(12):1614-6.
Specific protein patterns characterize metastatic potential of advanced bladder cancer
Pilchowski R, Stöhr R, von Eggeling F, Hartmann A, Wunderlich H, Junker K
J Urol. 2011 Aug;186(2):713-20.
The plasmacytoid carcinoma of the bladder–rare variant of aggressive urothelial carcinoma.
Keck B, Stoehr R, Wach S, Rogler A, Hofstaedter F, Lehmann J, Montironi R, Sibonye M, Fritsche HM, Lopez-Beltran A, Epstein JI, Wullich B, Hartmann A
Int J Cancer. 2011 Jul 15;129 (2):346-54.
S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer.
Nawroth R, Stellwagen F, Schulz WA, Stoehr R,Hartmann A, Krause BJ, Gschwend JE, Retz M
PLoS One. 2011;6(11):e27509
Blasenkarzinom – Update
R. Nawroth, A. Hartmann, P.J. Olbert, A.S. Merseburger, R. Stöhr, R. Knüchel, M. Retz, S. Füssel Urologe 2011 50:221-226
Hartmann A, Zanardo L, Bocker-Edmonston T, Blaszyk H, Dietmaier W, Stoehr R, Cheville JC, Junker K, Wieland W, Knuechel R, Rueschoff J, Hofstädter F, Fishel R (2002). Frequent Microsatellite Instability in Sporadic Tumors of the Upper Urinary Tract. Cancer Res. 62, 6796-6802
Eble JN (2004) Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC Press.
Muscle-invasive urothelial carcinoma of the bladder. Detection and topography of micrometastases in lymph nodes
Autenrieth M, Nawroth R, Semmlack S, Gschwend JE, Retz M.
EMMPRIN (CD147). A new key protein during tumor progression in bladder cancer
Nawroth R, Stöhr R, Hartmann A, Gschwend JE, Retz M.
The latest news on bladder cancer
Retz M, Lehmann J, Nawroth R, Gschwend JE.
German Association for Bladder Cancer Research
Retz M, Hartmann A, Merseburger A, Olbert P, Stoehr R, Nawroth R.